Brind.

Truist Financial set a $90.00 price target on Edwards Lifesciences shares, and TD Cowen reaffirmed its buy rating and raised the price objective.

9 reports, 4 independent Updated Oct 24
Gone quiet
Reports
9
Developments
3
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Truist Financial set a $90.00 price target on Edwards Lifesciences shares, and TD Cowen reaffirmed its buy rating and raised the price objective.

Who's involved

What this event is mainly about
Edwards LifesciencesTruist FinancialTD Cowen

How it developed

Newest first. Tap a step to see who reported it.
  1. Multiple analysts, including Barclays and Citigroup, updated their ratings for Edwards Lifesciences.1 source
  2. RBC and Truist Financial raised price targets for Edwards Lifesciences.1 source
  3. Analyst coverage on Edwards Lifesciences from Truist Financial and TD Cowen.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story